CGA IGC SPONSORED WEBINAR
[GI-Cancer Case Studies] Capture More Patients & Families Who Can Benefit from Hereditary Cancer Testing:
Utilizing the Natera Hereditary Cancer Alert Program and Oncologist Initiated Testing
Date: Wednesday, February 12th, 2025
Time: 7:00 PM ET | 4:00 PM PT (60-minute webinar)
Registrants will receive a recording of the webinar approximately one week after the event.
Join Dr. Shruti Singh, Medical Oncologist / Hematologist at Northwest Cancer Centers, Natera and CGA IGC for a 60-minute webinar to discuss how providers in the Oncology clinic can initiate hereditary cancer testing through the new Natera Hereditary Cancer Alert Program to capture more patients who can benefit from genetic information.
“The Natera Hereditary Cancer Alert Program made me feel more confident that there is a safety net that is capturing those patients for me… I am an early adopter of Signatera, which offers a more holistic view while also getting baseline labwork, and providers can order Signatera and the Empower Hereditary Cancer Test at same time - so why wouldn’t you utilize these tools?”
- Dr. Shruti Singh
Webinar Objectives:
- Explore how to implement oncologist / clinician initiated hereditary cancer testing into workflows and the resulting impact on patient outcomes
- Learn how the new Natera Hereditary Cancer Alert Program (HCAP) works to help identify more patients who meet testing guidelines in Oncology clinics
- Review patient case studies in GI-cancers that utilize these tools to help inform patient treatment and management decisions
- Discover how the Natera Oncology portfolio, including the Signatera™ Molecular Residual Disease (MRD) Test and the Empower™ Hereditary Cancer Test, can support patients from diagnosis to survivorship
Hear from our speakers
Shruti Singh, MD
Medical Oncology/Hematology
Northwest Cancer Centers
Dr. Shruti Singh is a medical oncologist/hematologist practicing in a community setting. Dr. Singh received her medical degree at the University of Tennessee Health Science Center College of Medicine in 2013. She went on to complete her Internal Medicine residency and Hematology/Oncology fellowship at Loyola University Medical Center. Dr. Singh served as Chief Fellow at Loyola during her fellowship.
Dr. Singh’s clinical interests are focused on benign and malignant hematology as well as women's oncology, thoracic and genitourinary malignancies. She also has a special interest in geriatric oncology. Post treatment, she focuses on cancer survivorship and prevention.
Her prior research focused on outcomes of sequential immunotherapy, outcomes of elderly patients undergoing hematopoietic stem cell transplants and outcomes of elderly patients with aggressive Non-Hodgkin’s lymphoma.
Dr. Singh is a member of the American Society for Hematology and American Society of Clinical Oncology. Dr. Singh entered clinical practice and joined Northwest Cancer Centers at the Dyer location in 2019.
Adam ElNaggar, MD
Medical Director, Oncology
Natera
Dr. Adam ElNaggar joined Natera in 2021 as the Medical Director for genitourinary and gynecologic cancers. Prior to this, he was at West Cancer Center and Research Institute where he served as Director of Gynecologic Cancer Research, Associate Fellowship Director, and on the National Comprehensive Cancer Network (NCCN) ovarian cancer panel.
Dr. ElNaggar earned his medical degree at Indiana University School of Medicine and completed his residency in obstetrics and gynecology at the University of Tennessee Health Science Center in Memphis, TN. He then completed his fellowship in gynecologic oncology at The Ohio State University Comprehensive Cancer Center.
Asaf Maoz, MD
Medical Oncology, Dana-Farber Cancer Institute
CGA IGC
Dr. Maoz is an attending physician in the Division of Genetics and Prevention and the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, and a member of the faculty at Harvard Medical School. He received his undergraduate degree, Summa Cum Laude, and his medical degree from the Hebrew University.
Dr. Maoz trained in Internal Medicine at Boston University, where he was inducted into the Alpha Omega Alpha Honor society. He then pursued fellowship training in Oncology at Dana-Farber/Mass General Brigham. He also completed postdoctoral fellowships at the University of Southern California, and the Whitehead Institute for Biomedical Research. Dr. Maoz's research focuses on the detection and prevention of hereditary cancers and the treatment of cancers of the gastrointestinal tract.
The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the tests. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2025 Natera, Inc. All Rights Reserved.
13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy